RecommendationLoE GoRScreening with LDCT lowdose computed topographyReduces lung cancerrelated mortality in highrisk subjectsheavy smokers 30 packyears or 15 years since cessationaged 55 ID: 938892
Download Pdf The PPT/PDF document "cell lung cancer NSCLCESMO Clinical Prac..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
cell lung cancer (NSCLC)ESMO Clinical Practice Guidelines for diagnosis, treatm
ent and follow RecommendationLoE, GoRScreening with LDCT (low-dose computed top
ography)Reduces lung cancer-related mortality in high-risk subjects(heavy smoke
rs [! 30 pack-years or " 15 years since cessation]aged 55Ð74 years)!Questions r
emain about the definition of the at Tissue procurementBronchoscopyà,!EBUS/EUS
mediastinal nodes*CT-guided biopsyMediastinoscopy*Tests needed for clinical sta
ging Screening for brain metastases by MRI might be useful in patients consider
ed for curative therapyàDepending on site and size of tumour with biopsy/aspira
tion/brush/washing!Bronchoscopy is usually sufficient to diagnose NSCLC, though
may not allow a detailed sub-classificationWork Ischaemicheart disease*1.5Hist
ory of cerebrovascular disease 1.5Serum creatinine � 2 mg/dL1Pneumonecto
my planned1.5Class groupingsA0B1Ð1.5C2Ð2.5D� 2.5*Ischaemicheart disease:
history of myocardial Recalibrated thoracic revised cardiac risk indexStaging
and risk assessment s been made to ensure that treatment and other information
are presented accurately in this publication, the ultimate responsibility rest
s withthe prescribing physician. Neither the publisher nor the ESMO Guidelines
Committee can be held responsible for errors or for any consequencesarising fro
m the use of information contained herein. For detailed prescribing information
on the use of any product or procedure discussed herein, please consult the pr
escribing information or instructional material issued by the manufacturer.The
slide set can be used as a quick reference guide to access key content on evide
nce-based management and individual slides may be used for personal presentatio
n in their present version and without any alterations. All rights reserved.© 2
018 European Society for Medical OncologyPlease visit www.esmo.orgor oncologypr
o.esmo.orgto view the full guidelines.Disclaimer and how to obtain more informa